918331-73-4

Usage

Uses

Used in Organic Synthesis:
4-Chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid is used as a building block in organic synthesis for the preparation of various pharmaceuticals and agrochemicals. Its unique structure and reactivity allow for further chemical modifications and functionalizations, enhancing its utility in diverse research and development processes.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-Chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid is used as a key intermediate for the synthesis of biologically active compounds. Its boron-containing group serves as a versatile handle for further chemical modifications, enabling the development of new drugs with improved therapeutic properties.
Used in Industrial Applications:
4-Chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid is also utilized in various industrial applications due to its potential to be incorporated into materials with specific properties. Its unique structure and reactivity contribute to the development of innovative products and technologies in different sectors.

Upstream product

• 42860-10-6 3-bromo-4-chlorobenzoic acid 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1057393-55-1 4-chloro-N-cyclopropyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 1214882-15-1 4-chloro-3-(8-(2,4-difluorophenyl)-1-methyl-2-oxo-1,2-dihydropyrido[3,2-d]pyridazin-3-yl)benzoic acid 

Relevant academic research and scientific papers

NOVEL COMPOUNDS HAVING EFFECTS OF TREATING INFLAMMATORY DISEASE AS P38 MAP KINASE INHIBITOR

The present invention relates to novel compounds exhibiting anti-inflammatory activity. The compound of the present invention plays a critical role in the production of inflammatory prodrug (pro-inflammatory cytokines) and has an excellent inhibitory effe

Novel, Self-Assembling Dimeric Inhibitors of Human β Tryptase

β-Tryptase, a homotetrameric serine protease, has four identical active sites facing a central pore, presenting an optimized setting for the rational design of bivalent inhibitors that bridge two adjacent sites. Using diol, hydroxymethyl phenols or benzoyl methyl hydroxamates, and boronic acid chemistries to reversibly join two [3-(1-acylpiperidin-4-yl)phenyl]methanamine core ligands, we have successfully produced a series of self-assembling heterodimeric inhibitors. These heterodimeric tryptase inhibitors demonstrate superior activity compared to monomeric modes of inhibition. X-ray crystallography validated the dimeric mechanism of inhibition, and compounds demonstrated high selectivity against related proteases, good target engagement, and tryptase inhibition in HMC1 xenograft models. Screening 3872 possible combinations from 44 boronic acid and 88 diol derivatives revealed several combinations that produced nanomolar inhibition, and seven unique pairs produced greater than 100-fold improvement in potency over monomeric inhibition. These heterodimeric tryptase inhibitors demonstrate the power of target-driven combinatorial chemistry to deliver bivalent drugs in a small molecule form.

New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors

This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.

NEW 3-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES

This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.

BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS

New bicyclic derivatives of formula (I), wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as p38 kinase inhibitors.